Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Linezolid Surveillance Results for the United States: LEADER Surveillance Program 2011

Linezolid Surveillance Results for the United States: LEADER Surveillance Program 2011 Linezolid Surveillance Results for the United States: LEADER Surveillance Program 2011 Robert K. Flamm a , Rodrigo E. Mendes a , James E. Ross a , Helio S. Sader a and Ronald N. Jones a , b a JMI Laboratories, North Liberty, Iowa, USA b Tufts University School of Medicine, Boston, Massachusetts, USA ABSTRACT The LEADER surveillance program monitors the in vitro activity of linezolid and comparator agents against Gram-positive bacteria in the United States. In its eighth consecutive year (2011), a total of 60 medical centers from the United States, including seven medical centers specializing in children's health care contributed a total of 7,303 Gram-positive pathogens. The MIC 90 value for Staphylococcus aureus was 2 μg/ml, and for coagulase-negative staphylococci, enterococci, Streptococcus pneumoniae , β-hemolytic streptococci, and viridans group streptococci, the MIC 90 was 1 μg/ml. The “all organism” linezolid-resistant and nonsusceptible rate was only 0.19%. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Antimicrobial Agents and Chemotherapy American Society For Microbiology

Linezolid Surveillance Results for the United States: LEADER Surveillance Program 2011

Linezolid Surveillance Results for the United States: LEADER Surveillance Program 2011

Antimicrobial Agents and Chemotherapy , Volume 57 (2): 1077 – Feb 1, 2013

Abstract

Linezolid Surveillance Results for the United States: LEADER Surveillance Program 2011 Robert K. Flamm a , Rodrigo E. Mendes a , James E. Ross a , Helio S. Sader a and Ronald N. Jones a , b a JMI Laboratories, North Liberty, Iowa, USA b Tufts University School of Medicine, Boston, Massachusetts, USA ABSTRACT The LEADER surveillance program monitors the in vitro activity of linezolid and comparator agents against Gram-positive bacteria in the United States. In its eighth consecutive year (2011), a total of 60 medical centers from the United States, including seven medical centers specializing in children's health care contributed a total of 7,303 Gram-positive pathogens. The MIC 90 value for Staphylococcus aureus was 2 μg/ml, and for coagulase-negative staphylococci, enterococci, Streptococcus pneumoniae , β-hemolytic streptococci, and viridans group streptococci, the MIC 90 was 1 μg/ml. The “all organism” linezolid-resistant and nonsusceptible rate was only 0.19%.

Loading next page...
 
/lp/american-society-for-microbiology/linezolid-surveillance-results-for-the-united-states-leader-LljJhxSIFx

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
American Society For Microbiology
Copyright
Copyright © 2013 by the American society for Microbiology.
ISSN
0066-4804
eISSN
1098-6596
DOI
10.1128/AAC.02112-12
pmid
23254424
Publisher site
See Article on Publisher Site

Abstract

Linezolid Surveillance Results for the United States: LEADER Surveillance Program 2011 Robert K. Flamm a , Rodrigo E. Mendes a , James E. Ross a , Helio S. Sader a and Ronald N. Jones a , b a JMI Laboratories, North Liberty, Iowa, USA b Tufts University School of Medicine, Boston, Massachusetts, USA ABSTRACT The LEADER surveillance program monitors the in vitro activity of linezolid and comparator agents against Gram-positive bacteria in the United States. In its eighth consecutive year (2011), a total of 60 medical centers from the United States, including seven medical centers specializing in children's health care contributed a total of 7,303 Gram-positive pathogens. The MIC 90 value for Staphylococcus aureus was 2 μg/ml, and for coagulase-negative staphylococci, enterococci, Streptococcus pneumoniae , β-hemolytic streptococci, and viridans group streptococci, the MIC 90 was 1 μg/ml. The “all organism” linezolid-resistant and nonsusceptible rate was only 0.19%.

Journal

Antimicrobial Agents and ChemotherapyAmerican Society For Microbiology

Published: Feb 1, 2013

There are no references for this article.